Background: Basal cell carcinoma is one of the most common types of non-melanoma skin cancers, which can be locally destructive despite low-rate metastasis. Surgery is the treatment of choice, but it lacks of efficacy on advanced cases. Hedgehog pathway inhibitors are a class of drugs providing a new therapeutic option for patients affected by advanced disease. Besides systemic therapy, such as vismodegib and sonidegib, also topical inhibitors have been developed. Patidegib is able to decrease tumor burden, reducing the adverse effects induced by systemic targeted therapies. Methods: We performed comprehensive research to summarize the use of patidegib in advanced and recurrent aggressive basal cell carcinomas. Only English language human studies were included in the search. Results: Seven trials reported the application of patidegib. Both topical and systemic patidegib demonstrated safety, tolerability, and efficacy in naive patients with stage II and III basal cell carcinomas, while stage IV disease and not-naive patients did not show any benefit. Conclusion: Unlike systemic Hedgehog pathway inhibitors, patidegib 2% gel is not associated with systemic adverse effects and allows a better patient management. Considering the multidisciplinary management of neoplasia, in the era of precision medicine, it is mandatory to confide in pharmacogenomics to obtain personalized combined or sequential therapies.

Cosio, T., Di Prete, M., Di Raimondo, C., Garofalo, V., Lozzi, F., Lanna, C., et al. (2021). Patidegib in Dermatology: A Current Review. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(19), 10725 [10.3390/ijms221910725].

Patidegib in Dermatology: A Current Review

Orlandi, Augusto;Bianchi, Luca;Campione, Elena
2021-10-03

Abstract

Background: Basal cell carcinoma is one of the most common types of non-melanoma skin cancers, which can be locally destructive despite low-rate metastasis. Surgery is the treatment of choice, but it lacks of efficacy on advanced cases. Hedgehog pathway inhibitors are a class of drugs providing a new therapeutic option for patients affected by advanced disease. Besides systemic therapy, such as vismodegib and sonidegib, also topical inhibitors have been developed. Patidegib is able to decrease tumor burden, reducing the adverse effects induced by systemic targeted therapies. Methods: We performed comprehensive research to summarize the use of patidegib in advanced and recurrent aggressive basal cell carcinomas. Only English language human studies were included in the search. Results: Seven trials reported the application of patidegib. Both topical and systemic patidegib demonstrated safety, tolerability, and efficacy in naive patients with stage II and III basal cell carcinomas, while stage IV disease and not-naive patients did not show any benefit. Conclusion: Unlike systemic Hedgehog pathway inhibitors, patidegib 2% gel is not associated with systemic adverse effects and allows a better patient management. Considering the multidisciplinary management of neoplasia, in the era of precision medicine, it is mandatory to confide in pharmacogenomics to obtain personalized combined or sequential therapies.
Pubblicato
Rilevanza internazionale
Recensione
Esperti anonimi
Settore MED/35
English
IPI-926
basal cell carcinoma
hedgehog signaling inhibitors
patidegib
targeted cancer therapy
Antineoplastic Agents
Biphenyl Compounds
Clinical Trials as Topic
Hedgehog Proteins
Humans
Prognosis
Pyridines
Signal Transduction
Skin Neoplasms
Treatment Outcome
Veratrum Alkaloids
Dermatology
Molecular Targeted Therapy
Cosio, T., Di Prete, M., Di Raimondo, C., Garofalo, V., Lozzi, F., Lanna, C., et al. (2021). Patidegib in Dermatology: A Current Review. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 22(19), 10725 [10.3390/ijms221910725].
Cosio, T; Di Prete, M; Di Raimondo, C; Garofalo, V; Lozzi, F; Lanna, C; Dika, E; Orlandi, A; Rapanotti, Mc; Bianchi, L; Campione, E
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Patidegib in Dermatology.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 450.45 kB
Formato Adobe PDF
450.45 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/304606
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact